Sars-CoV2
Conditions
Brief summary
A novel zoonotic coronavirus was discovered in Wuhan (Hubei Province, China) mid-December 2019 and was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus rapidly spread to the rest of the world, including Europe and explicitly affects the respiratory system, generating Coronavirus disease 2019 (COVID-19). This study is a monocentric interventional prospective cohort study. After signing a written informed consent, participants will be recruited for questionnaire completion and blood sampling. Sample storage and analysis will be performed at the laboratory of microbiology of the UZ Brussel. * To document SARS-CoV-2 seroprevalence among employees of the UZ Brussel at day 0 (i.e. at beginning of the study, planned early May 2020), month 2 and month 5. * To document number of SARS-CoV-2 seroconversions among employees of the UZ Brussel over a period of 5 months.
Interventions
DIAGNOSTIC_TESTSerological testing
Antibody testing for Sars-COV-2 antibodies in blood.
Sponsors
Universitair Ziekenhuis Brussel
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Any adult employee of the UZ Brussel who provided a signed informed consent to participate in the study.
Exclusion criteria
* UZ Brussel employees whose contract expires within 6 months of study initiation, with the exception of resident trainees (if training continues in another hospital, resident trainees will be asked to perform the last sampling when leaving the UZ Brussel). * Staff not active during the inclusion period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Seroprevalence | Change from baseline to 2 months and 5 months timepoint | \- To document SARS-CoV-2 seroprevalence among employees of the UZ Brussel at day 0 (i.e. at beginning of the study, planned early May 2020), month 2 and month 5. |
| seroconversions | Change from baseline to 2 months and 5 months timepoint | \- To document number of SARS-CoV-2 seroconversions among employees of the UZ Brussel over a period of 5 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Antibody kinetics | Change from baseline to 2 months and 5 months timepoint | \- To document the SARS-CoV-2 antibody kinetics after confirmed and probable COVID-19. Specifically (1) electrostatic interactions, (2) dispersion forces, (3) hydrogen bonds, and (4) hydrophobic interactions. |
| Potential work-related risk factors | Change from baseline to 2 months and 5 months timepoint | \- To investigate potential work-related risk factors for SARS-CoV-2 infection among employees of the UZ Brussel. |
| Incidence of definite cases | Change from baseline to 2 months and 5 months timepoint | \- To document the incidence of new definite cases of COVID-19 (based on self-reported positive PCR testing on nasopharyngeal swab) among employees of the UZ Brussel over a period of five months. |
| Concerns for safety for infection with COVID-19 | Change from baseline to 2 months and 5 months timepoint | \- To document the concerns of HCW and non-HCW about their safety for infection with COVID-19. |
| Proportion of asymptomatic seroconversions | Change from baseline to 2 months and 5 months timepoint | \- To quantify the proportion of asymptomatic seroconversions among employees of the UZ Brussel over a period of five months. |
| Incidence of probable cases | Change from baseline to 2 months and 5 months timepoint | \- To document the incidence of new probable cases of COVID-19 (based on study questionnaire) among employees of the UZ Brussel over a period of five months. |
Countries
Belgium
Contacts
Primary ContactSabine Allard, MD
Backup ContactLaurien De Greef, Nurse
Outcome results
None listed